Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Peptalk Week in Review — November 13, 2026 cover art

Peptalk Week in Review — November 13, 2026

Peptalk Week in Review — November 13, 2026

Listen for free

View show details
About this listen
This week: the week's biggest story — the FDA orders a class-wide label warning on every GLP-1 drug, from Ozempic to Zepbound, over a rare eye condition, NAION: about 6.4 cases per 100,000 person-years on a GLP-1 against 3.8 on comparison treatments in 126 pooled trials, a small absolute risk with a serious consequence. Plus: the HHS peptide-compounding policy moves from paper to practice as Olympia Pharmaceuticals starts compounding BPC-157 for patients with a prescription, with the public comment window closing November 13 and state pharmacy boards pushing back; Pfizer lands up to $1.5 billion from Blackstone to fund ten Phase 3 trials of its once-monthly GLP-1 shot Berobenatide, with first approvals targeted for 2028; China approves Lilly's Orforglipron (Foundayo), the first GLP-1 weight-loss pill in the country, ahead of Novo's oral Wegovy.And quick hits on Health Canada seizing 11,400+ vials of contaminated unauthorized peptides, Pemvidutide's Phase 2 results in alcohol use disorder, and ObesityWeek opening November 14.For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.Sources:• U.S. Food and Drug Administration, Drug Safety Communication (Nov 9, 2026) — FDA requires safety labeling changes for GLP-1 receptor agonists due to potential increased risk of NAION (126 randomized trials, 134,253 patients, 15 probable NAION events; 6.4 vs 3.8 per 100,000 person-years): https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential• Pharmaceutical Executive (Nov 10, 2026) — FDA requests updated safety label warning across all GLP-1 receptor agonists for potential risk of NAION: https://www.pharmexec.com/view/fda-requests-safety-label-warning-glp-1-receptor-agonist-risk-naion• Olympia Pharmaceuticals, GlobeNewswire (Nov 12, 2026) — Olympia Pharmaceuticals to compound select peptides under HHS interim enforcement policy (503A pharmacy; BPC-157 first, then KPV, TB-500, MOTS-c, Semax, Epitalon; available by December; licensed in 49 states): https://rss.globenewswire.com/news-release/2026/11/12/3401699/0/en/olympia-pharmaceuticals-to-compound-select-peptides-under-hhs-interim-enforcement-policy.html• Federal Register, Doc. 2026-22192 (Docket HHS-OASH-2026-0496) — HHS enforcement discretion policy for 503A compounding of six peptides; public comment closes November 13, 2026: https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances• Reuters (Nov 11, 2026) — Pfizer secures up to $1.5 billion from Blackstone for obesity drug development (Berobenatide, once-monthly GLP-1; 10 Phase 3 trials; first approvals targeted 2028; Metsera acquisition up to $10 billion): https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-secures-up-15-billion-blackstone-obesity-drug-development-2026-11-11/• BioPharma Dive (Nov 12, 2026) — Blackstone bets $1.5B on Pfizer's obesity drug: https://www.biopharmadive.com/news/blackstone-pfizer-berobenatide-deal/874483/• Reuters (Nov 12, 2026) — Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (Orforglipron / Foundayo; first oral GLP-1 weight-loss pill approved in China; Novo's oral Wegovy application pending): https://wnflsports.com/2026/11/12/china-approves-eli-lillys-weight-loss-pill-orforglipron/• Health Canada, public advisory RA-82930 (Nov 6, 2026) — Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs (11,400+ vials seized from Shanghai ERP Peptide Biotechnology Co. Ltd. and two Canadian online retailers; bacteria including Acinetobacter seifertii, Acinetobacter nosocomialis, Cutibacterium acnes): https://recalls-rappels.canada.ca/en/alert-recall/health-canada-warns-about-contaminated-unauthorized-injectable-peptides-and-non• Health Canada, public advisory (Nov 12, 2026) — Health Canada warns about unauthorized peptides, including contaminated injectable peptides sold by Sage & Summit Wellness Co. in Ottawa, ON: https://www.newswire.ca/news-releases/public-advisory-health-canada-warns-about-unauthorized-peptides-including-contaminated-injectable-peptides-sold-by-sage-amp-summit-wellness-co-in-ottawa-on-802173243.html• Altimmune, GlobeNewswire (Nov 9, 2026) — Altimmune reports positive Phase 2 RECLAIM results for Pemvidutide in alcohol use disorder (heavy drinking days −4.20/week vs −2.75 placebo; 42.2% with zero heavy drinking days vs 17.4% placebo; ~100 adults; presented at AASLD The Liver Meeting 2026, Denver; end-of-Phase 2 FDA meeting planned December 2026): https://www.quiverquant.com/news/Altimmune%20Reports%20Positive%20Phase%202%20RECLAIM%20Results%20for%20Pemvidutide%20in%20Alcohol%20Use%20Disorder%20and%20Announces%20FDA%20Meeting%20Plans%20for%...
adbl_web_anon_alc_button_suppression_t1
No reviews yet